Mizuho Securities USA LLC Has $15.32 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mizuho Securities USA LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,770 shares of the medical research company’s stock after selling 4,658 shares during the quarter. Mizuho Securities USA LLC’s holdings in Thermo Fisher Scientific were worth $15,322,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Integrated Investment Consultants LLC lifted its holdings in shares of Thermo Fisher Scientific by 34.2% during the third quarter. Integrated Investment Consultants LLC now owns 1,009 shares of the medical research company’s stock worth $624,000 after buying an additional 257 shares during the last quarter. German American Bancorp Inc. increased its position in shares of Thermo Fisher Scientific by 10.0% during the third quarter. German American Bancorp Inc. now owns 10,188 shares of the medical research company’s stock valued at $6,302,000 after purchasing an additional 927 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $235,000. Intech Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 8.8% during the third quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company’s stock valued at $2,114,000 after purchasing an additional 275 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Thermo Fisher Scientific by 4.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 180,801 shares of the medical research company’s stock valued at $111,838,000 after purchasing an additional 7,727 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.7 %

NYSE:TMO opened at $512.86 on Thursday. Thermo Fisher Scientific Inc. has a fifty-two week low of $476.45 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The stock has a market capitalization of $196.17 billion, a PE ratio of 32.15, a price-to-earnings-growth ratio of 3.37 and a beta of 0.79. The business’s 50-day simple moving average is $579.63 and its 200-day simple moving average is $580.98.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.69 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TMO shares. Bank of America boosted their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Royal Bank of Canada dropped their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 in the last ninety days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.